Most clot-bound thrombin activity is inhibited by plasma antithrombin during clot aging, but a very small fraction survives

Biol Pharm Bull. 2000 Apr;23(4):502-5. doi: 10.1248/bpb.23.502.

Abstract

Inhibitory effects of thrombin inhibitors against clot-bound thrombin have been evaluated using clots prepared from human plasma as the source of clot-immobilized active enzyme, and the clot-bound thrombin has been reported to be protected from its inhibition by antithrombin. However, we found that the clot-bound thrombin was not intrinsically protected from inhibition by antithrombin, i.e., a large fraction of initially active clot-bound thrombin was inhibited by antithrombin present in human plasma time dependently, and only very small fractions (0.04--0.08%) of the thrombin retained their enzymatic activity after clot-aging. These results suggest that the extent of clot-aging determines the sensitivity of clot-bound thrombin to antithrombin, and that inhibitory effects of drugs against clot-bound thrombin in vitro must be interpreted with caution to estimate their effects in vivo.

MeSH terms

  • Antithrombins / metabolism*
  • Fluorescent Dyes / metabolism
  • Heparin / pharmacology
  • Humans
  • Hydrolysis
  • Substrate Specificity
  • Thrombin / antagonists & inhibitors*
  • Thrombin / metabolism
  • Thrombosis / metabolism*

Substances

  • Antithrombins
  • Fluorescent Dyes
  • Heparin
  • Thrombin